GEN Exclusives

More »

GEN News Highlights

More »
Oct 19, 2007

GSK Licenses BioWa Tool for Antibody R&D

  • GlaxoSmithKline (GSK) gained access to BioWa's Potelligent® technology for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies.

    The agreement grants GSK nonexclusive rights to research and develop antibodies based on this platform for an undisclosed number of targets. In return, BioWa will receive an upfront payment and license fees.

    Potelligent improves potency and efficacy of antibody therapeutics by enhancing ADCC, according to BioWa. It reduces the amount of fucose in the carbohydrate structure of an antibody using a fucosyltransferase-knockout CHO cell line as a production cell.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?